Korean startups make global push at K-Venture Renaissance Forum

A total of nine startups presented investment proposals to both South Korean and international venture capitalists at the 2nd K-Venture Renaissance Forum. The event, which was held on Monday at Seoul National University of Science and Technology, highlighted Korean companies eager to expand their global presence.

Among them, MTEG, a company specializing in AI solutions for medical imaging, introduced technology that analyzes surgery and medical videos using AI, converting the results into valuable data assets. Fellow startup Roomer showcased “Book Now,” a web service allowing anyone to create reservation or order websites without coding. This platform integrates CRM functions that manage orders and customer data for marketing purposes.

Other notable participants included Neutune, which has developed an AI engine that assists content creators in producing copyright-free music across platforms such as YouTube. AIChemist launched an automated synthetic data generation platform based on digital twin technology, enabling immersive education and business systems tailored to user needs. Synerex, a company focused on real-time kinematic positioning-based global navigation satellite system (GNSS) devices, has reduced error margins to centimeter levels while ARBAIM developed the world’s first social review service (SRS) platform, greyd, which enables consumers to review products in short-form videos and purchase them.

BASGENBIO introduced its AI-based drug development platform, DEEPCT, which leverages genome cohort data. This platform is recognized as a solution that is central to providing evidence in the drug discovery process. PLABiologics, a faculty-led startup at CHA University, is working on stem cell therapies derived from placental tissue. The company is currently in licensing discussions with one of Japan’s largest biotech companies, which is expected to accelerate its entry into the Japanese market where stem cell therapy is booming. IMBdx, specializing in liquid biopsy, has developed a genetic analysis tool for early cancer detection. The company listed on the Kosdaq market in April 2024 under the special listing requirements.